jehan

Another busy week for Modus Outcomes!

On April 9th, in downtown New York City, we hosted our third ‘Patient-centered drug development: reflections, challenges & solutions’ workshop entitled: ‘Why we need to move to modern test theory: real world examples’. Once again, our roundtable event gathered a strong group of industry, academic and clinical representatives. Our external invited speakers included Professor Peter […]

Spotlight on … Duchenne muscular dystrophy (DMD) and Spinal muscular atrophy (SMA)

feet-619399_1920

Duchenne muscular dystrophy (DMD) and Spinal muscular atrophy (SMA) are rare neurodegenerative diseases, which cause progressive, proximal-to-distal muscular weakness leading to loss of ambulation and motor function. Worldwide, they are the leading cause of neuromuscular disorders affecting children, which has led to an active research field to discover new DMD and SMA therapies. Since 2013, […]